E-LIB Suche - Ergebnisse für: Rhee, Martin S.

1

Long-acting HIV Treatments: Study Design, Logistics, and Ac..:

Murdock, Nicholas A ; Alajaji, Nayri E ; Schaefer, Robin...
Open Forum Infectious Diseases. 11 (2024) 7 - p. , 2024

Link: https://doi.org/10.1093/..

2

Indirect Treatment Comparisons of Lenacapavir Plus Optimize..:

Chatzidaki, Iro ; Curteis, Tristan ; Luedke, Hannah...
Value in Health. 26 (2023) 6 - p. 810-822 , 2023

Link: https://doi.org/10.1016/..

3

Efficacy and safety of the novel capsid inhibitor lenacapav..:

Ogbuagu, Onyema ; Segal-Maurer, Sorana ; Ratanasuwan, Winai...
The Lancet HIV. 10 (2023) 8 - p. e497-e505 , 2023

Link: https://doi.org/10.1016/..

4

1585. Efficacy and safety of long-acting subcutaneous lenac..:

Ogbuagu, Onyema ; Segal-Maurer, Sorana ; Ratanasuwan, Winai...
Open Forum Infectious Diseases. 9 (2022) Supplement_2 - p. , 2022

Link: https://doi.org/10.1093/..

5

Resistance Analyses in Highly Treatment-Experienced People ..:

Margot, Nicolas A ; Naik, Vidula ; VanderVeen, Laurie...
The Journal of Infectious Diseases. 226 (2022) 11 - p. 1985-1991 , 2022

Link: https://doi.org/10.1093/..

6

Lenacapavir: a first-in-class HIV-1 capsid inhibitor:

Dvory-Sobol, Hadas ; Shaik, Naveed ; Callebaut, Christian.
Current Opinion in HIV and AIDS. 17 (2022) 1 - p. 15-21 , 2022

Link: https://doi.org/10.1097/..

7

Clinical targeting of HIV capsid protein with a long-acting..:

Link, John O. ; Rhee, Martin S. ; Tse, Winston C....
Nature. 584 (2020) 7822 - p. 614-618 , 2020

Link: https://doi.org/10.1038/..

8

937. Virally Suppressed PLH Switching From Abacavir to Teno..:

Funderburg, Nicholas ; Mccomsey, Grace ; Kulkarni, Manjusha...
Open Forum Infectious Diseases. 5 (2018) suppl_1 - p. S34-S34 , 2018

Link: https://doi.org/10.1093/..

9

Efficacy and safety of emtricitabine/tenofovir alafenamide ..:

Post, Frank A. ; Yazdanpanah, Yazdan ; Schembri, Gabriel...
HIV Clinical Trials. 18 (2017) 3 - p. 135-140 , 2017

Link: https://doi.org/10.1080/..

10

Brief Report: Long-Term (96-Week) Efficacy and Safety After..:

Raffi, François ; Orkin, Chloe ; Clarke, Amanda...
JAIDS Journal of Acquired Immune Deficiency Syndromes. 75 (2017) 2 - p. 226-231 , 2017

Link: https://doi.org/10.1097/..

11

Efficacy and Safety of Tenofovir Alafenamide vs. Tenofovir ..:

Flamm, Jason A ; Vanig, Thanes ; Gathe, Joseph...
Open Forum Infectious Diseases. 4 (2017) suppl_1 - p. S427-S428 , 2017

Link: https://doi.org/10.1093/..

12

Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazan..:

Gallant, Joel E. ; Koenig, Ellen ; Andrade-Villanueva, Jaime...
The Journal of Infectious Diseases. 208 (2013) 1 - p. 32-39 , 2013

Link: https://doi.org/10.1093/..

13

Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazan..:

Gallant, Joel E. ; Koenig, Ellen ; Andrade-Villanueva, Jaime...
The Journal of Infectious Diseases. 208 (2013) 1 - p. 32-39 , 2013

Link: http://dx.doi.org/10.109..

14

Cobicistat Versus Ritonavir as a Pharmacoenhancer of Atazan..:

Gallant, Joel E. ; Koenig, Ellen ; Andrade-Villanueva, Jaime...
The Journal of Infectious Diseases. 208 (2013) 1 - p. 32-39 , 2013

Link: https://www.jstor.org/st..

15

Relationship Between Plasma Protease Inhibitor Concentratio..:

Rhee, Martin S. ; Hellinger, James A. ; Sheble‐Hall, Sandy..
The Journal of Clinical Pharmacology. 50 (2010) 4 - p. 392-400 , 2010

Link: https://doi.org/10.1177/..